Overview

Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)

Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
A Study of Bafetinib as Treatment for Patients with Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL).
Phase:
Phase 2
Details
Lead Sponsor:
CytRx
Treatments:
Bafetinib